VolitionRx’s (VNRX) “Buy” Rating Reaffirmed at D. Boral Capital

D. Boral Capital reissued their buy rating on shares of VolitionRx (NYSE:VNRX) in a research report released on Wednesday,Benzinga reports. The firm currently has a $5.00 price objective on the stock.

A number of other analysts have also recently commented on the company. Benchmark reaffirmed a “hold” rating on shares of VolitionRx in a research note on Friday, November 22nd. StockNews.com initiated coverage on VolitionRx in a research note on Tuesday. They set a “sell” rating for the company.

VolitionRx Stock Down 4.5 %

NYSE:VNRX opened at $0.63 on Wednesday. The stock’s fifty day simple moving average is $0.65 and its 200-day simple moving average is $0.66. The firm has a market capitalization of $58.38 million, a P/E ratio of -1.75 and a beta of 1.20. VolitionRx has a 12-month low of $0.43 and a 12-month high of $1.23.

Insider Activity at VolitionRx

In related news, CEO Cameron John Reynolds purchased 139,811 shares of the stock in a transaction on Monday, December 9th. The shares were purchased at an average cost of $0.57 per share, with a total value of $79,692.27. Following the acquisition, the chief executive officer now directly owns 2,117,404 shares in the company, valued at $1,206,920.28. The trade was a 7.07 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Guy Archibald Innes bought 174,764 shares of the firm’s stock in a transaction dated Monday, December 9th. The stock was purchased at an average cost of $0.57 per share, for a total transaction of $99,615.48. Following the transaction, the director now directly owns 617,085 shares of the company’s stock, valued at $351,738.45. The trade was a 39.51 % increase in their position. The disclosure for this purchase can be found here. Over the last quarter, insiders have purchased 358,266 shares of company stock valued at $204,212. 12.80% of the stock is owned by insiders.

Institutional Inflows and Outflows

An institutional investor recently raised its position in VolitionRx stock. Ground Swell Capital LLC grew its stake in shares of VolitionRx Limited (NYSE:VNRX) by 78.8% during the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 45,959 shares of the company’s stock after buying an additional 20,249 shares during the quarter. Ground Swell Capital LLC’s holdings in VolitionRx were worth $28,000 as of its most recent SEC filing. 8.09% of the stock is owned by hedge funds and other institutional investors.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.